United States HR 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices.

Status: Referred to the Subcommittee on Health. (as of 2019-12-11)

State: United States · Session: 116 · Bill: HR 5382

Subjects: Health care coverage and access, Prescription drugs, Retail and wholesale trades

Sponsors: Jeff Fortenberry

View United States HR 5382 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.